Xianghong Zhang

Xianghong Zhang

Auto-generated profile, based on publicly available information

Xianghong Zhang

Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Cancer Research
Verified
Journal Article
Closed access
JZJing Zeng
Jing Zeng
ZLZhengjun Lin
Zhengjun Lin
XZXianghong Zhang
Xianghong Zhang
TZTao Zheng
Tao Zheng
HXHaodong Xu
Haodong Xu
TLTang Liu
Tang Liu
Neoantigens represent a class of antigens within tumor microenvironments that arise from diverse somatic mutations and aberrations specific to tumorigenesis, holding substantial promise for advancing tumor immunotherapy. However, only a subset of neoantigens effectively elicits antitumor immune responses, and the specific neoantigens recognized by individual T-cell receptors (TCR) remain incompletely characterized. Therefore, substantial research has focused on screening immunogenic neoantigens, mainly through their major histocompatibility complex (MHC) presentation and TCR recognition specificity. Given the resource intensiveness and inefficiency of experimental validation, predictive models based on artificial intelligence (AI) have gradually become mainstream methods to discover immunogenic neoantigens. In this article, we provide a comprehensive summary of current AI methodologies for predicting neoantigens, with a particular focus on their capability to model peptide–MHC (pMHC) and pMHC–TCR binding. Furthermore, a thorough benchmarking analysis was conducted to assess the performance of antigen presentation predictors for scoring the immunogenicity of neoantigens. AI models have potential applications in the treatment of clinical diseases although several limitations must first be overcome to realize their full potential. Anticipated advancements in data accessibility, algorithmic refinement, platform enhancement, and comprehensive validation of immune processes are poised to enhance the precision and utility of neoantigen prediction methodologies. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

2 July 2025
Verified
Other
Open access
JZJing Zeng
Jing Zeng
ZLZhengjun Lin
Zhengjun Lin
XZXianghong Zhang
Xianghong Zhang
TZTao Zheng
Tao Zheng
HXHaodong Xu
Haodong Xu
TLTang Liu
Tang Liu
Neoantigens represent a class of antigens within tumor microenvironments that arise from diverse somatic mutations and aberrations specific to tumorigenesis, holding substantial promise for advancing tumor immunotherapy. However, only a subset of neoantigens effectively elicits antitumor immune responses, and the specific neoantigens recognized by individual T-cell receptors (TCR) remain incompletely characterized. Therefore, substantial research has focused on screening immunogenic neoantigens, mainly through their major histocompatibility complex (MHC) presentation and TCR recognition specificity. Given the resource intensiveness and inefficiency of experimental validation, predictive models based on artificial intelligence (AI) have gradually become mainstream methods to discover immunogenic neoantigens. In this article, we provide a comprehensive summary of current AI methodologies for predicting neoantigens, with a particular focus on their capability to model peptide–MHC (pMHC) and pMHC–TCR binding. Furthermore, a thorough benchmarking analysis was conducted to assess the performance of antigen presentation predictors for scoring the immunogenicity of neoantigens. AI models have potential applications in the treatment of clinical diseases although several limitations must first be overcome to realize their full potential. Anticipated advancements in data accessibility, algorithmic refinement, platform enhancement, and comprehensive validation of immune processes are poised to enhance the precision and utility of neoantigen prediction methodologies.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

2 July 2025
Verified
Other
Open access
JZJing Zeng
Jing Zeng
ZLZhengjun Lin
Zhengjun Lin
XZXianghong Zhang
Xianghong Zhang
TZTao Zheng
Tao Zheng
HXHaodong Xu
Haodong Xu
TLTang Liu
Tang Liu
(For publication) Supplementary Table S1-S5 and Supplementary Fig. S1-S3